Form 10-Q Y-mAbs Therapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Y-mAbs Therapeutics (YMAB) PT Lowered to $25 at BMO Capital
August 12, 2024 4:08 PM EDTBMO Capital analyst Etzer Darout lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $25.00 (from $26.00) while maintaining a Outperform rating.
The analyst comments "YMAB reported 2Q24 total revenues of $22.8M, a touch below FactSet consensus (-0.9%) but ahead of our estimate (+3.6%).... More
